EXOME: Biotech • Healthcare • Life Sciences

Boston
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects

1.
Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4 | National
2.
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects | Boston
3.
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin | Boston
4.
Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies | Boston
5.
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma | San Diego
6.
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Boston

Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week

$300M

Arrowhead Pharmaceuticals, Takeda Pharmaceutical

Dewpoint Therapeutics Taps Ex-Sanofi Executive Ameet Nathwani as CEO

Invetx Appoints Bill Brondyk, Colin Giles to Executive Team

“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
Frank Vinluan | New York
FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats
Frank Vinluan | Europe
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
Frank Vinluan | National
Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility
Sue Sutter | Boston
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug
Frank Vinluan | National
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting
Editors | Boston
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter
Frank Vinluan | San Francisco
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs
Frank Vinluan | Boston
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B
Frank Vinluan | New York

Read More Posts ›

Underwriters and Partners

Xconomy Insight

From Our Editors · Podcast
Xcelerating Life Sciences Philadelphia: The Highlights Podcast
Becoming the Cell & Gene Therapy Hub

Sponsored · Whitepaper
How to Approach Life Sciences Fundraising
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Xconomy on Demand

We offer a number of ways to subscribe for free!